AnaptysBio (NASDAQ:ANAB) Given Outperform Rating at Leerink Partnrs

Leerink Partnrs reaffirmed their outperform rating on shares of AnaptysBio (NASDAQ:ANAB) in a report published on Tuesday, Zacks.com reports. Leerink Partnrs also issued estimates for AnaptysBio’s Q1 2024 earnings at ($1.41) EPS, Q2 2024 earnings at ($1.44) EPS, Q3 2024 earnings at ($1.45) EPS, Q4 2024 earnings at ($1.42) EPS, FY2024 earnings at ($5.71) EPS, Q1 2025 earnings at ($1.91) EPS, Q2 2025 earnings at ($1.86) EPS, Q3 2025 earnings at ($1.85) EPS, Q4 2025 earnings at ($1.14) EPS, FY2025 earnings at ($6.37) EPS, FY2026 earnings at ($4.82) EPS, FY2027 earnings at ($3.95) EPS and FY2028 earnings at ($3.39) EPS.

ANAB has been the topic of several other reports. JPMorgan Chase & Co. decreased their target price on shares of AnaptysBio from $30.00 to $28.00 and set a neutral rating on the stock in a report on Monday, April 1st. SVB Leerink initiated coverage on shares of AnaptysBio in a report on Tuesday. They issued an outperform rating and a $47.00 target price on the stock. Piper Sandler started coverage on shares of AnaptysBio in a report on Friday, February 16th. They issued an overweight rating and a $80.00 target price on the stock. Wedbush raised shares of AnaptysBio from a neutral rating to an outperform rating and boosted their price target for the company from $20.00 to $34.00 in a research note on Tuesday, March 12th. Finally, Stifel Nicolaus started coverage on shares of AnaptysBio in a research note on Wednesday, February 21st. They issued a buy rating and a $50.00 price target on the stock. One analyst has rated the stock with a sell rating, two have assigned a hold rating and eight have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of Moderate Buy and an average price target of $46.22.

AnaptysBio Trading Up 0.6 %

ANAB opened at $21.47 on Tuesday. The firm has a market capitalization of $574.54 million, a PE ratio of -3.53 and a beta of -0.30. AnaptysBio has a twelve month low of $13.36 and a twelve month high of $27.50. The firm’s 50-day moving average price is $23.38 and its 200 day moving average price is $20.55.

AnaptysBio (NASDAQ:ANAB) last posted its quarterly earnings results on Monday, March 11th. The biotechnology company reported ($1.59) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.74) by $0.15. The firm had revenue of $9.01 million for the quarter, compared to analyst estimates of $3.28 million. AnaptysBio had a negative net margin of 953.66% and a negative return on equity of 119.42%. As a group, analysts predict that AnaptysBio will post -6.25 earnings per share for the current fiscal year.

Insider Buying and Selling at AnaptysBio

In other AnaptysBio news, CEO Daniel Faga sold 3,000 shares of the stock in a transaction that occurred on Monday, March 25th. The shares were sold at an average price of $21.42, for a total value of $64,260.00. Following the sale, the chief executive officer now directly owns 749,087 shares of the company’s stock, valued at approximately $16,045,443.54. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. In other news, insider Eric J. Loumeau sold 5,000 shares of the company’s stock in a transaction on Friday, February 16th. The shares were sold at an average price of $25.00, for a total value of $125,000.00. Following the completion of the transaction, the insider now owns 3,240 shares in the company, valued at approximately $81,000. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, CEO Daniel Faga sold 3,000 shares of the company’s stock in a transaction on Monday, March 25th. The shares were sold at an average price of $21.42, for a total transaction of $64,260.00. Following the completion of the transaction, the chief executive officer now owns 749,087 shares of the company’s stock, valued at approximately $16,045,443.54. The disclosure for this sale can be found here. In the last three months, insiders have sold 157,005 shares of company stock valued at $3,586,199. Insiders own 35.50% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. Hudson Bay Capital Management LP boosted its holdings in shares of AnaptysBio by 100.0% in the 3rd quarter. Hudson Bay Capital Management LP now owns 100,000 shares of the biotechnology company’s stock valued at $1,796,000 after buying an additional 50,000 shares in the last quarter. Jacobs Levy Equity Management Inc. boosted its holdings in shares of AnaptysBio by 4.1% in the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 206,785 shares of the biotechnology company’s stock valued at $3,714,000 after buying an additional 8,064 shares in the last quarter. China Universal Asset Management Co. Ltd. boosted its holdings in shares of AnaptysBio by 350.4% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 3,072 shares of the biotechnology company’s stock valued at $66,000 after buying an additional 2,390 shares in the last quarter. Victory Capital Management Inc. acquired a new position in shares of AnaptysBio in the 3rd quarter valued at $785,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in AnaptysBio by 134.4% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,896 shares of the biotechnology company’s stock worth $106,000 after purchasing an additional 3,381 shares during the period.

AnaptysBio Company Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.